http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111876483-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111876483-B |
| titleOfInvention | Application of LYPD1 in the diagnosis, treatment, prognosis and prediction of recurrence of hepatocellular carcinoma |
| abstract | The invention relates to the application of the molecular marker LYPD1 gene in the diagnosis of liver cancer, differentiation of liver cancer, and prognosis of liver cancer. The invention selects and classifies the sequencing data and clinical information of liver cancer patients in the TCGA database, and obtains data analysis and liver cancer Differentially expressed genes related to differentiation were verified by clinical experiments, and the results showed that the expression of LYPD1 gene was highly correlated with the differentiation of liver cancer and the prognosis of liver cancer. The present invention provides a molecular marker closely related to the prognosis of liver cancer, which can be used to dynamically monitor the prognosis of patients with liver cancer treated with the FOLFOX regimen, and has important clinical significance and application prospects. |
| priorityDate | 2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.